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Abstract
Background
Ribavirin (RBV) is an essential component of most current hepatitis C (HCV) treatment regi-
mens and still standard of care in the combination with pegylated interferon (pegIFN) to
treat chronic HCV in resource limited settings. Study results in HIV/HCV-coinfected patients
are contradicting as to whether RBV concentration correlates with sustained virological
response (SVR).
Methods
We included 262 HCV treatment naïve HIV/HCV-coinfected Swiss HIV Cohort Study
(SHCS) participants treated with RBV and pegIFN between 01.01.2001-01.01.2010, 134
with HCV genotype (GT) 1/4, and 128 with GT 2/3 infections. RBV levels were measured
retrospectively in stored plasma samples obtained between HCV treatment week 4 and end
of therapy. Uni- and multivariable logistic regression analyses were used to evaluate the
association between RBV concentration and SVR in GT 1/4 and GT 2/3 infections. The
analyses were repeated stratified by treatment phase (week 4-12, 13-24, >24) and IL28B
genotype (CC versus CT/TT).
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Results
SVR rates were 35.1% in GT 1/4 and 70.3% in GT 2/3 infections. Overall, median RBV con-
centration was 2.0 mg/L in GT 1/4, and 1.9 mg/L in GT 2/3, and did not change significantly
across treatment phases. Patients with SVR had similar RBV concentrations compared to
patients without SVR in both HCV genotype groups. SVR was not associated with RBV lev-
els2.0 mg/L (GT 1/4, OR 1.19 [0.5-2.86]; GT 2/3, 1.94 [0.78-4.80]) and2.5 mg/L (GT 1/
4, 1.56 [0.64-3.84]; GT 2/3 2.72 [0.85-8.73]), regardless of treatment phase, and IL28B
genotype.
Conclusion
In HIV/HCV-coinfected patients treated with pegIFN/RBV, therapeutic drug monitoring of
RBV concentrations does not enhance the chance of HCV cure, regardless of HCV geno-
type, treatment phase and IL28B genotype.
Introduction
According to the World Health Organization, more than 185 million people globally have been
infected with hepatitis C virus (HCV) [1]. In the last decade, the combination of ribavirin
(RBV) and pegylated interferon (pegIFN) was the standard of care for treatment of chronic
HCV infection. With the availability of direct-acting antivirals (DAAs), new treatment options
with high cure rates for HIV/HCV-coinfected patients are available now. However, RBV is still
a component of many of these regimens [2]. In addition, pegIFN/RBV remains standard of
care in in resource limited settings because of financial constraints [1].
Hemolytic anemia is a common adverse effect of RBV, especially with higher dosages and
prolonged therapy. RBV dose reduction and discontinuation are associated with reduced sus-
tained virological response (SVR) rates [3]. Despite weight-adjusted dose regimens, interindi-
vidual RBV plasma concentrations vary widely [4, 5]. In contrast, intraindividual variations are
low and may be explained by the extensive volume of distribution and slow clearance from
deep pharmacokinetic compartments [5, 6]. Steady-state concentrations are reached after 4
weeks [7]. Due to the large interindividual variability in RBV concentrations and a narrow
therapeutic range, RBV therapeutic drug monitoring may be worthwhile to increase the likeli-
hood of SVR while avoiding adverse events.
Some studies postulated that the level of RBV is a major determinant for SVR in the era of
pegIFN/RBV in HIV/HCV-coinfected patients. However, this issue remains controversial
(reviewed in [8]). In addition, data are inconsistent regarding the time point of plasma RBV
concentration monitoring during treatment, and whether certain patient groups may benefit
more than others. Therefore, we aimed here to assess the impact of RBV steady-state concen-
tration on SVR at different treatment time points and in different HIV/HCV-coinfected patient
groups treated with pegIFN/RBV in the Swiss HIV Cohort Study (SHCS).
Methods
Swiss HIV Cohort Study (SHCS)
The SHCS is an ongoing, prospective cohort study that continuously enrolls and observes
HIV-infected adults at five university outpatient clinics, two large district hospitals, affiliated
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regional hospitals, and private practices, since 1988 [9]. Demographic, clinical and laboratory
data are collected at registration and every six months thereafter using a standard protocol.
The protocol was approved by local ethical review boards (Kantonale Ethik-Kommission
Zürich, Kantonale Ethikkommission Bern, Ethikkommission beider Basel, Comite d’Ethique
Geneve, Commission Cantonale d’Ethique Lausanne, Ethikkommission Kanton St.Gallen,
Comitato etico cantonale Ticino), and written informed consent, including genetic analyses,
was obtained from each patient. For this study, in addition to the information retrieved from
the SHCS database, detailed information on HCV-infection, on treatment history and out-
comes was obtained by retrospective structured and standardized chart review.
Patient Selection
We included all HCV treatment naïve SHCS participants in the analyses with pegIFN/RBV
therapy between 1 January 2001 and 1 January 2010, known HCV genotype (GT) and treat-
ment response as well as availability of stored plasma samples from HCV treatment week 4
onwards for RBV concentration measurement. Patients with early therapies in acute HCV
infections were excluded. None of the patients were on regimens containing DAAs. All patients
received a standard regimen of weight-based RBV given twice a day and subcutaneous pegIFN.
Due to the retrospective analysis of ribavirin plasma concentrations, the measured RBV con-
centrations did not have any influence on patients’ care.
Laboratory Measurements and Genotyping
Blood samples were drawn semiannually at HIV cohort visits and stored at -80°C. RBV con-
centration was measured retrospectively in samples taken during HCV therapy between week
4 and the end of treatment. Plasma RBV concentrations were determined by high-performance
liquid chromatography tandem mass spectrometry (LC-MS/MS) on a Finnigan TSQ 7000
(ThermoQuest, San Jose, USA) according to a validated and accredited method. It was shown
before that RBV concentration remains stable under various storage conditions, including tem-
peratures of -20°C and -80°C [10, 11]. Genotyping for IL28B SNP rs12979860 was done only in
patients with available consent for genetic analyses. Genotyping was performed by using a cus-
tom TaqMan assay from Applied Biosystems as described by Ge et al [12].
Definitions
HCV treatment outcome was defined as SVR, respectively non-SVR, including non-responders
and relapsers, according to standard definitions [2]. SVR was defined as at least one negative
HCV RNA test12 weeks after the end of treatment [2]. A treatment course was considered
terminated if pegIFN was discontinued for30 days. Liver fibrosis stage was derived from
liver biopsy using the METAVIR scoring system [13] or from transient elastography (Fibros-
can, Echosens S.A.S.U., Paris, France), with a cutoff value of>12.5 kPa for Metavir F4 (Cirrho-
sis) [14]. Undetectable HIV RNA was defined as values<50 copies/mL.
Statistical Analysis
A receiver operating characteristic (ROC) curve was used to determine the plasma RBV cut-off
point that best discriminates between patients who achieved SVR and those who did not. Addi-
tionally, RBV plasma concentrations were dichotomized using the median RBV concentration
of 2.0 mg/L in our cohort as the cutoff value. In addition, we performed also analyses with a
higher cutoff value of 2.5 mg/L. For the overall treatment phase and for patients with more
than one RBV concentration value per treatment phase we used the mean value. Median RBV
Ribavirin Concentration Level and Sustained Virological Response
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values in the different treatment phases (week 4–12, 13–24,>24) were compared using the
Wilcoxon rank-sum test. Since not all patients contributed samples for all treatment periods,
we compared the demographic characteristics of the patients of the different treatment periods
with chi-square and Kruskal-Wallis tests.
Univariable and multivariable logistic regression analyses were used to evaluate the associa-
tion between RBV concentration levels and SVR. Analyses were done separately for HCV
genotypes (GT) 1 or 4, and 2 or 3, respectively, because of the known different SVR rates for
those two GT groups. Variables significantly associated with SVR in the univariable analyses
and those considered to be clinically relevant were included in the multivariable model. Fixed
covariables included sex, age, HIV transmission group, HCV RNA level, IL28B genotype, CD4
cell count, and antiretroviral therapy (ART) at HCV treatment start. Logistic regression analy-
ses were further explored by using two different RBV concentration cutoff levels, and by strati-
fying by treatment phase and IL28B genotypes (CC versus CT/TT), respectively. All statistical
analyses were performed using StataMP 13.1 (Stata Corp, College Station, USA).
Results
Study Population
We included 262 SHCS participants who fulfilled the inclusion criteria (Fig 1). Of those, 134
patients had HCV GT 1 or 4, and 128 GT 2 or 3 infections, respectively (Table 1). Among all
included patients, the proportion of men was 72% and median age at HCV treatment start was
42 years. In 71% of the patients HIV was transmitted by intravenous drug use (IDU). Only 15/
262 (6%) had CD4 cell counts less than 200 cells/μL and 81% were on antiretroviral therapy
(ART) at HCV treatment start. Cirrhosis was present in 31% of participants. The IL28B CC
genotype was documented in 51/116 (44%) persons with GT 1/4, and in 60/116 (52%) with GT
2/3 (in 30/262 patients genotyping was not performed because of missing genetic consent).
SVR was achieved in 47/134 (35.1%) persons with GT 1/4, and in 90/128 (70.3%) with GT 2/3
infections. Baseline characteristics of patients stratified by HCV genotype (GT 1/4 vs.2/3) are
shown in Table 1.
RBV Plasma Concentration Levels
A total of 394 RBV drug levels were determined between week 4 and end of therapy. Number
of patients with available RBV concentrations per genotype group and treatment phase is out-
lined in Fig 1. The patients contributing to the different treatment phases did not differ with
regards to age, sex and transmission category (all p>0.06) besides patients from treatment
phase week 4–12 versus 13–24 with GT 2/3 regarding transmission mode (p = 0.006) and age
(p = 0.03). Overall median RBV plasma level was 2.0 mg/L in GT 1/4 and 1.9 mg/L in GT 2/3
infections (Table 2). Median RBV concentration was similar for all treatment phases (no signif-
icant difference between week 4–12, 13–24, and>24 in both genotype groups; all p-values
>0.3). Since ROC analyses were not able to detect clearly discriminating cutoff values of RBV
plasma concentration for the prediction of SVR, we dichotomized RBV levels as lower versus
equal as or higher than the median (2.0 mg/L). In addition we also performed analyses using
2.5 mg/L as a cutoff (Table 2).
Impact of RBV Concentration on SVR
In patients with SVR RBV concentration was similar compared to patients without SVR,
regardless of HCV genotype and treatment phase (Fig 2). RBV drug levels2.0 mg/L and2.5
mg/L were not significantly associated with SVR in both genotype groups (GT 1/4,2.0 mg/L
Ribavirin Concentration Level and Sustained Virological Response
PLOS ONE | DOI:10.1371/journal.pone.0133879 July 28, 2015 4 / 11
OR 1.19 [0.5–2.86];2.5 mg/L 1.56 [0.64–3.84]; GT 2/3,2.0 mg/L 1.94 [0.78–4.80],2.5
mg/L 2.72 [0.85–8.73]). In the multivariable regression analyses, IL28B genotype CC was a
strong positive predictor for SVR in both genotype groups (GT 1/4, OR 3.96 [1.66–9.44],
p = 0.002; GT 2/3, 3.02 [1.18–7.73], p = 0.02). A high HCV viral load was inversely correlated
with HCV cure in GT 1/4 (0.38 [0.15–0.94], p = 0.04). Age, sex, and HIV transmission group
had no significant influence on HCV treatment outcome (Table 3).
When we analyzed the association between RBV concentration and SVR in different treat-
ment phases, neither RBV levels2.0 mg/L, nor levels2.5 mg/L in any of the treatment
phases were significantly associated with HCV cure (Fig 3). When analyses were stratified by
HCV genotype and IL28B genotype, RBV concentration levels remained without a significant
impact on SVR in any group (Fig 3).
Fig 1. Patient flowchart.
doi:10.1371/journal.pone.0133879.g001
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Discussion
Several trials evaluated the impact of RBV therapeutic drug monitoring on SVR. Study results,
however, remained controversial. We therefore assessed the correlation between RBV concen-
tration and HCV cure in a large treatment naïve HIV/HCV-coinfected cohort treated with
pegIFN/RBV. We found no difference in RBV concentrations between patients with and with-
out SVR. RBV concentration levels2.0 mg/L and2.5 mg/L were not associated with HCV
cure, regardless of HCV genotype, treatment phase (week 4–12, 13–24,>24), and IL28B geno-
type. Overall, median RBV concentrations were 2.0 mg/L in GT 1/4 and 1.9 mg/L in GT 2/3
infections, and there were no significant differences between treatment phases.
RBV concentrations2.0 mg/L, as well as2.5 mg/L, did not differentiate between patients
responding to HCV therapy and those not. In line with our results, there are previous studies
in mono- and coinfected patients that did not find an association between RBV concentration
and virologic response [10, 15, 16]. However, there are also several other studies showing such
a correlation. In coinfected patients, RBV cutoffs of 1.6 mg/L [17], 2.0 mg/L [18], 2.3 mg/L [6],
and 2.5mg/L [19] were established to improve treatment efficacy. Reasons for the contradicting
Table 1. Patient characteristics at hepatitis C virus (HCV) treatment start, treatment duration and sustained virologic response (SVR) according to
HCV genotype group.
Variable Genotype 1 and 4 Genotype 2 and 3
n = 134 n = 128
Sex, n (%) Male 98 (73.1) 90 (70.3)
Female 36 (26.9) 38 (29.7)
Age, years, median (IQR) 42 (39–45) 42 (38–46)
Age, years <45 90 (67.2) 85 (66.4)
45 44 (32.8) 43 (33.6)
HIV transmission group (%) MSM 16 (11.9) 8 (6.3)
IDU 95 (70.9) 92 (71.9)
Heterosexual 14 (10.5) 26 (20.3)
Other 9 (6.7) 2 (1.6)
HCV RNA, available n (%) 131 (97.8) 126 (98.4)
<800’000 IU/ml 52 (38.8) 58 (45.3)
800’000 IU/ml 79 (59.0) 68 (53.1)
Fibrosis score, available n (%) 93 (69.4) 84 (65.6)
Metavir <F4 62/93 (66.7) 61/84 (72.6)
Metavir F4 31/93 (33.3) 23/84 (27.4)
IL28B, available n (%) 116 (86.6) 116 (90.6)
CC 51/116 (44.0) 60/116 (51.7)
CT, TT 65/116 (56.0 56/116 (48.3)
CD4 cells/μl, (%) <200 6 (4.5) 9 (7.0)
200–349 19 (14.2) 29 (22.7)
350 109 (81.3) 90 (69.5)
Not on ART 19 (14.2) 31 (23.4)
On AR with HIV RNA undetectable 100 (74.6) 91 (71.1)
with HIV RNA detectable 15 (11.2) 6 (4.7)
HCV treatment duration, weeks median (IQR) 47.9 (27.6–50.4) 47.4 (26.4–49.0)
SVR, n (%) 47 (35.1) 90 (70.3)
Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C virus; IDU, intravenous drug user; IQR, interquartile range; MSM, men who have sex with
men; SVR, sustained viral response.
doi:10.1371/journal.pone.0133879.t001
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results may be small patient numbers, heterogeneity of populations and different clinical
settings.
Previous trials showed that monitoring of RBV concentrations at weeks 4, 12, 24 (reviewed
in [20]) or at treatment end [21] was associated with higher cure rates, while other studies only
found a correlation of RBV concentration and increased response rates in difficult-to-treat
Table 2. Ribavirin plasma concentration overall and in different treatment phases.
Treatment phase Overall Week 4–12 Week 13–24 Week >24
GT 1/4 GT 2/3 GT 1/4 GT 2/3 GT1/4 GT 2/3 GT 1/4 GT 2/3
n = 134 n = 128 n = 52 n = 49 n = 57 n = 62 n = 78 n = 69
RBV plasma level, median (IQR),
mg/L
2.0 (1.5–
2.8)
1.9 (1.5–
2.5)
2.0 (1.5–
2.8)
1.7 (1.5–
2.4)
2.0 (1.5–
2.7)
2.0 (1.5–
2.4)
1.9 (1.4–
2.8)
2.1 (1.5–
2.7)
RBV plasma level, n
(%)
<2 mg/L 67 (50.0) 67 (52.3) 26 (50.0) 30 (61.2) 27 (47.4) 31 (50.0) 41 (52.6) 30 (43.5)
2 mg/L 67 (50.0) 61 (47.7) 26 (50.0) 19 (38.8) 30 (52.6) 31 (50.0) 37 (47.4) 39 (56.5)
RBV plasma level, n
(%)
<2.5 mg/
L
92 (68.7) 94 (73.4) 35 (67.3) 38 (77.6) 40 (70.2) 48 (77.4) 51 (65.4) 46 (66.7)
2.5 mg/
L
42 (31.3) 34 (26.6) 17 (32.7) 11 (22.5) 17 (29.8) 14 (22.6) 27 (34.6) 23 (33.3)
Abbreviations: GT, genotype; IQR, interquartile range; RBV, ribavirin.
doi:10.1371/journal.pone.0133879.t002
Fig 2. Comparison of ribavirin concentrations between HIV/HCV-coinfected patients with and without sustained virological response (SVR),
stratified by HCV genotype and treatment phase. Abbreviations: SVR, sustained virological response; 0, no SVR; 1, SVR.
doi:10.1371/journal.pone.0133879.g002
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patient groups, including GT 1 and 4 infections [6, 17], GT 1 coinfected patients with CT/TT
IL28B genotypes [18], and African Americans with the CT/TT genotypes [22]. In our study,
RBV concentrations at any treatment time point did not predict SVR. Moreover, we could not
confirm that monitoring RBV steady-state levels may play a more important role in the
achievement of HCV cure in patients with a higher risk of treatment failure.
Median RBV steady state concentrations of 2.0 mg/L in GT 1/4 and 1.9 mg/L in GT 2/3 in
our cohort were similar as in other cohorts of HIV/HCV-coinfected [18] and HCV-monoin-
fected patients with values ranging from 1.4 to 2.5 mg/L [5, 21]. In a recently published study,
RBV area under the curve (AUC0-4h) within the first hours after RBV intake was significantly
lower in a small group of coinfected compared to monoinfected persons. The conclusion was
that lower early bioavailability of RBV could be one of the reasons for lower SVR rates in coin-
fected patients [23]. Our results with similar RBV steady state concentrations in coinfected
compared to monoinfected patients of other cohorts, do not support this hypothesis.
The overall SVR rates of 35.1% in GT 1/4 and 70.3% in GT 2/3 infections were high com-
pared to other HIV/HCV-coinfected cohorts and similar to cure rates achieved in randomized
Table 3. Uni- andmultivariable logistic regression analyses regarding factors associated with sustained virological response (SVR), stratified by
HCV genotype group.
Genotypes 1 and 4 Genotypes 2 and 3
n = 134 n = 128
Univariable Analysis Multivariable Analysis Univariable Analysis Multivariable Analysis
OR (95% C.I.) P-
value
OR (95% C.I.) P-
value
OR (95% C.I.) P-
value
OR (95% C.I.) P-
value
Age, years <45 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
45 0.59 (0.27–
1.29)
0.1 0.46 (0.18–
1.17)
0.1 1.14 (0.51–
2.56)
0.8 1.12 (0.43–
2.91)
0.8
Sex male 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
female 0.63 (0.27–
1.46)
0.3 0.40 (0.14–
1.16)
0.09 2.33 (0.92–
5.89)
0.08 1.96 (0.64–
6.04)
0.2
HIV transmission group, Non-IDU 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
IDU 0.52 (0.24–
1.13)
0.1 0.56 (0.22–
1.42)
0.2 0.88 (0.37–
2.06)
0.8 0.83 (0.31–
2.22)
0.7
HCV RNA, IU/ml <800’000 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
800’000 0.42 (0.20–
0.87)
0.02 0.38 (0.15–
0.94)
0.04 0.78 (0.36–
1.70)
0.5 0.76 (0.31–
1.86)
0.5
IL28B CT, TT 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
CC 3.19 (1.45–
7.00)
0.004 3.96 (1.66–
9.44)
0.002 2.67 (1.14–
6.25)
0.02 3.02 (1.18–
7.73)
0.02
CD4 cell count, cells/μl <200 1 (Ref.) 1 (Ref.)
200 0.52 (0.10–
2.70)
0.4 3.26 (0.82–
12.88)
0.09
Not on ART 1 (Ref.) 1 (Ref.)
On ART 0.91 (0.33–
2.51)
0.9 0.62 (0.24–
1.60)
0.3
RBV concentration, all FUP
time
<2 mg/L 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
2 mg/L 1.27 (0.63–
2.60)
0.5 1.19 (0.50–
2.86)
0.7 1.29 (0.60–
2.77)
0.5 1.94 (0.78–
4.80)
0.2
Abbreviations: ART, antiretroviral therapy; C.I., conﬁdence interval; FUP, follow-up; IDU, intravenous drug user; OR, odds ratio; RBV, ribavirin.
doi:10.1371/journal.pone.0133879.t003
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controlled trials [24–26]. In a large cohort of US veterans, SVR was 16.7% in GT 1 and 44% in
GT 2/3 infections during the same time period [27]. In our cohort, main predictors for SVR in
both HCV genotype groups were IL28B genotype CC and low HCV RNA levels at baseline,
which is in accordance with the results from other studies [19, 27, 28].
Major strengths of this study include the large number of patients and RBV concentration
measurements in a nation-wide representative cohort of HIV-infected patients in a real-life set-
ting. The large sample size was sufficient to allow separate analyses for GT1/4 and GT 2/3
HCV infections, and stratification by treatment phase and IL28B genotype. Limitations include
the retrospective study design. We did not collect RBV trough plasma concentrations. However
because of RBVs long elimination half-life and a stable steady-state after week 4, timing of sam-
ple collection is less relevant.
The new standard of care for HCV is DAA containing regimens, but RBV is still an essential
backbone in many of these therapies. Our cohort does not yet provide information on the role
of RBV drug monitoring in patients treated with DAA regimens. However, our data support
current guidelines recommending weight-adapted RBV doses with close clinical monitoring
and dose reduction, respectively discontinuation, in patients with signs of toxicity (dose-
response relationship) rather than ribavirin concentration measurements (concentration-
Fig 3. Impact of ribavirin level2.0 mg/L and2.5 mg/L on sustained virological response (SVR), stratified by HCV genotype group, treatment
phase and IL28B genotype.Multivariable logistic regression analysis, adjusted for age, sex, HIV transmission group and HCV RNA level. Abbreviations: CI,
confidence interval; HCV, hepatitis C virus; OR, odds ratio; RBV, ribavirin.
doi:10.1371/journal.pone.0133879.g003
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response relationship) [2], www.hcvguidelines.org). In resource limited settings where RBV/
pegIFN is still standard of care and financial opportunities and laboratory infrastructure are
limited our data does not support a role for RBV therapeutic drug monitoring [1].
In conclusion, we did not find a correlation between RBV plasma concentration and SVR,
regardless of HCV genotype, treatment phase and IL28B genotype. Our data do not support
RBV therapeutic drug monitoring in HIV/HCV-coinfected patients treated with pegIFN/RBV
to enhance the chance of HCV cure.
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